Radium of radium Curie used the residues after extraction of uranium from pitchblende. The uranium had been extracted by dissolution in sulfuric acid leaving radium sulfate, which is similar to barium sulfate but even less soluble in the residues. The residues also contained rather substantial amounts of barium sulfate which thus acted as a carrier for the radium sulfate. The first steps of the radium extraction process involved boiling with sodium hydroxide followed by hydrochloric acid treatment to remove as much as possible of other compounds. The remaining residue was then treated with sodium carbonate to convert the barium sulfate into
Radium Drug Administration in 2013 for use in medicine as a cancer treatment of bone metastasis. The main indication of treatment with Xofigo is the therapy of bony metastases from castration-resistant prostate cancer due to the favourable characteristics of this alpha-emitter radiopharmaceutical. Ra has also been used in experiments concerning therapeutic irradiation, as it is the only reasonably long-lived radium isotope which does not have radon as one of its daughters. Radium is still used today as a radiation source in some industrial radiography devices to check for flawed metallic parts, similarly to X-ray imaging. When mixed with beryllium, radium acts